Rare Disease Report
Physicians
Physicians
Patients & Caregivers

Huntingtons Disease

Teva Pharmaceutical Industries announced that the FDA has accepted the resubmission of the New Drug Application (NDA) for SD-809 (deutetrabenazine) to treat chorea associated with Huntington disease (HD).
Teva Pharmaceutical's treatment for Tardive Dyskinesia (TD) showed a statistically significant results in its Phase 3 trial.
VX15, a monoclonal antibody towards semaphorin 4D, is in a phase 2 clinical trial for the treatment of Huntington's disease. The antibody has also been given orphan drug designation by the FDA.
Samuel Franks, MD of Beth Israel Deaconess medical Center discusses the efficacy of SD-809 to treat chorea and dystonia in patients with Huntington's disease.
The Huntington's Disease Society of America (HDSA) is the nation's leading nonprofit agency dedicated to serve those with Huntington's disease (HD).
Company to Continue Talking With FDA and EMA To Hopefully Design a Confirmatory Study.
A DNA repair gene may, ironically, be associated with the damage that occurs on Huntington's disease.
Copyright © RareDR 2013-2017 Rare Disease Communications. All Rights Reserved.